IRONHealthcare · BiotechnologyIRON Stock Forecast: Disc Medicine, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Disc Medicine, Inc. hold a median 12-month price target of $100 — +79.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
IRON stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Disc Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (63): The share price has been relatively steady.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
IRON stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +79.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Sept 2026 | Wells Fargo | Maintains | Overweight | $79 → $86 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $100 |
| 2 Sept 2026 | Wedbush | Maintains | Outperform | — |
| 2 Sept 2026 | Wedbush | Maintains | Outperform | $88 → $100 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $118 → $120 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 16 June 2026 | Morgan Stanley | Maintains | Overweight | $80 → $85 |
| 10 June 2026 | Wedbush | Reiterates | Outperform | — |
| 10 June 2026 | Wedbush | Reiterates | Outperform | $88 |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 2 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 17 Feb 2026 | BMO Capital | Maintains | Outperform | — |
| 17 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 17 Feb 2026 | Stifel | Maintains | Buy | — |
| 17 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 17 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 16 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 10 Nov 2025 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRON appears on the weeks it earns a place.
IRON vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Disc Medicine, Inc. returned −23.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IRON analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Disc Medicine, Inc. (IRON) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.0×
- Price / sales
- —
- Price / book
- 3.6×
- EV / EBITDA
- −6.2×
Cheaper than 66% of US stocks
Cheaper than 26% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −39.1%
- Return on assets
- −24.0%
- Dividend yield
- 0.0%
Higher than 24% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Disc Medicine, Inc. (IRON) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Disc Medicine, Inc. has a market value of $2.3B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$245.9M.
Free cash flow in the twelve months to 30 June 2026: −$197.6M.
Trailing P/E: 5.0×; forward P/E: −8.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Disc Medicine, Inc. employs 165 people.
Data provided by Twelve Data
IRON vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Disc Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about IRON stock
What is the IRON stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Disc Medicine, Inc. have a median 12-month price target of $100, with estimates ranging from $83 to $128. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRON stock a buy right now?
Of the 13 analysts covering Disc Medicine, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Disc Medicine, Inc. 33 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRON?
As at 13 Oct 2026, Disc Medicine, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).
Will IRON stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +79.4% from the last close, and Ticker Nerd's factor model ranks Disc Medicine, Inc. 33 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRON stock forecast for 2030?
No analyst covering Disc Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $128 over the next 12 months.
How has IRON stock performed over the past year?
Disc Medicine, Inc. returned -23.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Disc Medicine, Inc. do?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases.
About Disc Medicine, Inc.
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s work centers on red blood cell biology, with programs designed to address disorders involving heme biosynthesis and iron homeostasis. Its current pipeline includes therapies in development for rare blood diseases such as erythropoietic porphyrias, Diamond-Blackfan anemia, anemia associated with myelofibrosis, and polycythemia vera. Disc Medicine operates as a research-driven biotech business, advancing both clinical and preclinical candidates aimed at modifying fundamental biological pathways rather than offering broad commercial products. Headquartered in Watertown, Massachusetts, Disc Medicine plays a specialized role in the hematology market by concentrating on diseases with significant unmet medical need and limited treatment options.
CEO Dr. John D. Quisel Esq., J.D., Ph.D. · 165 employees · United States · https://www.discmedicine.com